Genomill Health Eyes Clinical Adoption of Targeted NGS Technology

Turku, Finland – 18.8.2025 – We’re excited to be featured in GenomeWeb for our recent clinical study on Bridge Capture™, our targeted NGS technology.

As sequencing gets cheaper, sample preparation must evolve. Bridge Capture is built for this shift – fast, simple, scalable – and we’re ready to bring it into clinical use.

In a pilot work with colorectal cancer samples, Bridge Capture showed strong concordance with established methods and even uncovered additional oncogenic mutations. The workflow delivers results in ~4 hours, works from just a few nanograms of DNA, enables early sample pooling, and scales to any panel size.

“Our study supports the potential use of Bridge Capture in clinical settings, but further validation is required. According to our data, its sensitivity and accuracy are sufficient for clinical ctDNA analysis in most applications.” – Ari Ristimäki, Professor of Pathology, University of Helsinki, and senior author of the study

“Even though sequencing itself has been getting cheaper, the way of getting your sample DNA to sequencing libraries has not changed all that much. We want to change that.” – Manu Tamminen, CEO & Cofounder

👉 Read the full article in GenomeWeb for more details
📄 Read the full study in Scientific Reports